Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis

被引：0
|
作者：
Husni, M. Elaine [1 ]
Griffith, Jenny [2 ]
Betts, Keith [3 ]
Song, Yan [4 ]
Ganguli, Arijit [2 ]
机构：
[1] Cleveland Clin, Dept A50, Rheumatol, Cleveland, OH 44106 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Anal Grp Inc, Los Angeles, CA USA
[4] Anal Grp Inc, Boston, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2505
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
    M. Elaine Husni
    Keith A. Betts
    Jenny Griffith
    Yan Song
    Arijit Ganguli
    Rheumatology International, 2017, 37 : 1423 - 1434
  • [2] Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
    Husni, M. Elaine
    Betts, Keith A.
    Griffith, Jenny
    Song, Yan
    Ganguli, Arijit
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (09) : 1423 - 1434
  • [3] BENEFIT-RISK ANALYSIS OF ADALIMUMAB AND ALTERNATIVE TREATMENTS FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS
    Hicks, K. A.
    Earnshaw, S. R.
    Shaw, J. W.
    Cifaldi, M.
    VALUE IN HEALTH, 2012, 15 (07) : A439 - A440
  • [4] Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Conaghan, Philip
    Cohen, Stanley
    Burmester, Gerd
    Mysler, Eduardo
    Nash, Peter
    Tanaka, Yoshiya
    Rigby, William
    Patel, Jayeshkumar
    Shaw, Tim
    Betts, Keith A.
    Patel, Pankaj
    Liu, Jianzhong
    Sun, Rochelle
    Fleischmann, Roy
    RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 191 - 206
  • [5] What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment
    Alten, Rieke
    Nieto-Gonzalez, Juan Carlos
    Jacques, Peggy
    Montecucco, Carlomaurizio
    Moots, Robert
    Radner, Helga
    Vonkeman, Harald E.
    Heidenreich, Sebastian
    Whichello, Chiara
    Krucien, Nicolas
    Van Beneden, Katrien
    RMD OPEN, 2024, 10 (01):
  • [6] Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Philip Conaghan
    Stanley Cohen
    Gerd Burmester
    Eduardo Mysler
    Peter Nash
    Yoshiya Tanaka
    William Rigby
    Jayeshkumar Patel
    Tim Shaw
    Keith A. Betts
    Pankaj Patel
    Jianzhong Liu
    Rochelle Sun
    Roy Fleischmann
    Rheumatology and Therapy, 2022, 9 : 191 - 206
  • [7] Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study
    Gisbert, Javier P.
    Schreiber, Stefan
    Siegel, Corey A.
    Magro, Fernando
    Jus, Anna
    Whichello, Chiara
    Michaels-Igbokwe, Christine
    Heidenreich, Sebastian
    Oortwijn, Alessandra
    Vermeire, Severine
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [8] Benefit-Risk or Risk-Benefit Trade-offs? Another Look at Attribute Ordering Effects in DCEs
    Heidenreich, S.
    Beyer, A.
    Flamion, B.
    Ross, M.
    Seo, J.
    Marsh, K.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2019, 12 (04): : 433 - 433
  • [9] Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis
    Mauer, Jonathan
    Bullok, Kristin
    Watt, Stephen
    Whalen, Ed
    Russo, Leo
    Junor, Rod
    Markman, John
    Hauber, Brett
    Tervonen, Tommi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3837 - 3846
  • [10] Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis
    Mikuls, TR
    Moreland, LW
    DRUG SAFETY, 2003, 26 (01) : 23 - 32
12345